These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 12534150)
1. Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer. Thomas M Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):20-7. PubMed ID: 12534150 [TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Silvestri GA; Rivera MP Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869 [TBL] [Abstract][Full Text] [Related]
3. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663 [TBL] [Abstract][Full Text] [Related]
4. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Wolf M; Swaisland H; Averbuch S Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131 [TBL] [Abstract][Full Text] [Related]
5. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Herbst RS Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801 [TBL] [Abstract][Full Text] [Related]
7. The epidermal growth factor receptor as a novel target for cancer therapy: case studies and clinical implications. Riddle J; Lee P; Purdom M Semin Oncol Nurs; 2002 Nov; 18(4 Suppl 4):11-9. PubMed ID: 12534149 [TBL] [Abstract][Full Text] [Related]
11. ZD1839 (Iressa): what's in it for the patient? Natale RB; Zaretsky SL Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785 [TBL] [Abstract][Full Text] [Related]
12. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633 [TBL] [Abstract][Full Text] [Related]
13. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. Natale RB J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S128-30. PubMed ID: 18520295 [TBL] [Abstract][Full Text] [Related]
14. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941 [TBL] [Abstract][Full Text] [Related]
15. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145 [TBL] [Abstract][Full Text] [Related]
16. ZD1839 (Iressa) in non-small cell lung cancer. Herbst RS; Kies MS Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783 [TBL] [Abstract][Full Text] [Related]
17. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer. Pizzo B Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925 [TBL] [Abstract][Full Text] [Related]
18. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Cohen MH; Williams GA; Sridhara R; Chen G; Pazdur R Oncologist; 2003; 8(4):303-6. PubMed ID: 12897327 [TBL] [Abstract][Full Text] [Related]
19. Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. Kuiper JL; Heideman DA; Würdinger T; Grünberg K; Groen HJ; Smit EF Clin Lung Cancer; 2015 Jan; 16(1):60-6. PubMed ID: 25242669 [TBL] [Abstract][Full Text] [Related]
20. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK; J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]